Kalmar Investments’s Jazz Pharmaceuticals JAZZ Stock Holding History

Kalmar Investments’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-149,860	Closed	-$16.3M	–	99
2016 Q4	$16.3M	Sell	149,860 -21,135	-12%	-$2.35M	0.84%	60
2016 Q3	$20.8M	Sell	170,995 -7,905	-4%	-$1.07M	0.95%	43
2016 Q2	$25.3M	Buy	178,900 +45,435	+34%	+$6.7M	1.12%	33
2016 Q1	$17.4M	Sell	133,465 -122,250	-48%	-$15.2M	0.72%	62
2015 Q4	$35.9M	Buy	255,715 +4,005	+2%	+$555K	0.88%	51
2015 Q3	$33.4M	Buy	251,710 +92,475	+58%	+$15.9M	0.79%	56
2015 Q2	$28M	Sell	159,235 -580	-0.4%	-$104K	0.53%	71
2015 Q1	$27.6M	Buy	+159,815	New	+$27.4M	0.51%	73

Other funds holding JAZZ

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

CCM

Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Kalmar Investments's JAZZ Position: Q1 2017 in Review

Kalmar Investments sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2017, closing a stake of 149,860 shares — an estimated $16.3M sold.

Kalmar Investments first reported a position in JAZZ in Q1 2015 and held it in 8 quarters. The position peaked at $35.9M in Q4 2015. 306 funds tracked by Wall St. Rank hold JAZZ as of Q1 2017.

Kalmar Investments reported no remaining Jazz Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Kalmar Investments sold 149,860 Jazz Pharmaceuticals shares in Q1 2017, an estimated $16.3M.
Kalmar Investments first reported a position in Jazz Pharmaceuticals in Q1 2015 and held it in 8 quarters.
Kalmar Investments's Jazz Pharmaceuticals position peaked at $35.9M in Q4 2015.
306 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2017.

Based on Kalmar Investments's 13F filing for Q1 2017, filed 26 Apr 2017.